InMed Pharmaceuticals (INM) Depreciation & Amortization (IS): 2021-2025
Historic Depreciation & Amortization (IS) for InMed Pharmaceuticals (INM) over the last 4 years, with Sep 2025 value amounting to $53,202.
- InMed Pharmaceuticals' Depreciation & Amortization (IS) fell 2.52% to $53,202 in Q3 2025 from the same period last year, while for Sep 2025 it was $211,462, marking a year-over-year decrease of 3.59%. This contributed to the annual value of $212,839 for FY2025, which is 3.08% down from last year.
- Latest data reveals that InMed Pharmaceuticals reported Depreciation & Amortization (IS) of $53,202 as of Q3 2025, which was up 0.85% from $52,752 recorded in Q2 2025.
- In the past 5 years, InMed Pharmaceuticals' Depreciation & Amortization (IS) registered a high of $55,234 during Q4 2023, and its lowest value of $28,532 during Q3 2021.
- Over the past 3 years, InMed Pharmaceuticals' median Depreciation & Amortization (IS) value was $53,463 (recorded in 2023), while the average stood at $53,618.
- As far as peak fluctuations go, InMed Pharmaceuticals' Depreciation & Amortization (IS) surged by 71.91% in 2022, and later fell by 4.97% in 2023.
- InMed Pharmaceuticals' Depreciation & Amortization (IS) (Quarterly) stood at $49,797 in 2021, then decreased by 1.50% to $49,049 in 2022, then grew by 12.61% to $55,234 in 2023, then dropped by 3.68% to $53,202 in 2024, then decreased by 2.52% to $53,202 in 2025.
- Its Depreciation & Amortization (IS) was $53,202 in Q3 2025, compared to $52,752 in Q2 2025 and $52,306 in Q1 2025.